A Successful Launch of a New Oncology Product Requires Global Teams & Planning
CHAPEL HILL, N.C., Nov. 1, 2012 /PRNewswire/ -- Global Strategic Marketing (GSM) organizations in oncology and other critical therapeutic areas often face crowded markets that require high performance and proficiency to be successful.
Add to this increasing regulatory challenges, regional differences and the competitive nature of the oncology marketplace and it is easy to understand why GSM organizations to constantly assess their budgets and resource planning strategies to ensure a successful product launch.
To help marketing leaders throughout the pharma and medical device industries better equip their global strategy groups, Best Practices, LLC conducted and delivered "Oncology Global Strategic Marketing: Benchmarking Budget Levels & Service Scope," a primary research study which identifies essential insights for Oncology-GSM leaders in budgeting and strategic planning.
This report seeks to help companies understand the investment levels, marketing activities, timing and structures needed to successfully steer products and pipeline programs through the complex Oncology marketplace.
Executives can use this 75-page report to compare their global strategic marketing budget, staffing and services levels with industry averages to enhance their current practices.
Sample study benchmarks available in this report include:
- GSM staffing benchmarks by role, by development phase, by number of oncology programs and per $100M in oncology sales
- Outsourced and in-house labor dedicated to traditional and emerging markets
- GSM organizational structure
- Role of the GSM function for activities such as market intelligence, marketing, advocacy and KOL management
- Spending benchmarks around key GSM activities within marketing, market intelligence and advocacy
- Oncology GSM spending by phase of clinical development
Research participants included Global Strategic Marketing leaders supporting oncology organizations at 17 companies, including 11 of the Top 25 pharma companies. The study included both large, established and small, emerging oncology companies to provide broadest insights.
A complimentary excerpt of the research report is available at: http://www3.best-in-class.com/rr1185.htm.
For more information on this study and other recent primary research studies, contact us at 919.403.0251 or at firstname.lastname@example.org.
BEST PRACTICES, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies.
The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.
Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.
SOURCE Best Practices, LLC